BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-06
225 industry Phase 2/3 trial readout(s) and 45 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2025-06-02 | Complete response letter | complete response | ResQ Pharma | ()) (4) (20% soybean oil emulsion), for intravenous infusion | CRL 2025-06-02: ResQ Pharma NDA 217382 (()) (4) (20% soybean oil emulsion), for intravenous infusion) |
| 2025-06-03 | FDA approval | approved | MERCK SHARP DOHME MRK | KEYTRUDA | Approved 2025-06-03: KEYTRUDA (BLA125514 SUPPL173) |
| 2025-06-03 | FDA approval | approved | BAYER HEALTHCARE | NUBEQA | Approved 2025-06-03: NUBEQA (NDA212099 SUPPL8) |
| 2025-06-05 | FDA approval | approved | AZURITY | XIFYRM | Approved 2025-06-05: XIFYRM (NDA218395 ORIG1) |
| 2025-06-05 | FDA approval | approved | AZURITY | WIDAPLIK | Approved 2025-06-05: WIDAPLIK (NDA219423 ORIG1) |
| 2025-06-06 | FDA approval | approved | ASTELLAS | VYLOY | Approved 2025-06-06: VYLOY (BLA761365 SUPPL3) |
| 2025-06-06 | FDA approval | approved | MERCK SHARP DOHME MRK | KEYTRUDA | Approved 2025-06-06: KEYTRUDA (BLA125514 SUPPL183) |
| 2025-06-09 | FDA approval | approved | FRESENIUS KABI USA | ROCURONIUM BROMIDE | Approved 2025-06-09: ROCURONIUM BROMIDE (NDA217472 ORIG1) |
| 2025-06-09 | FDA approval | approved | MERCK SHARP DOHME MRK | ENFLONSIA | Approved 2025-06-09: ENFLONSIA (BLA761432 ORIG1) |
| 2025-06-10 | FDA approval | approved | BEONE MEDICINES USA ONC | BRUKINSA | Approved 2025-06-10: BRUKINSA (NDA218785 ORIG1) |
| 2025-06-10 | FDA approval | approved | BEONE MEDICINES USA ONC | BRUKINSA | Approved 2025-06-10: BRUKINSA (NDA218785 ORIG2) |
| 2025-06-10 | FDA approval | approved | ABBVIE ABBV | MAVYRET | Approved 2025-06-10: MAVYRET (NDA215110 SUPPL5) |
| 2025-06-10 | FDA approval | approved | ABBVIE ABBV | MAVYRET | Approved 2025-06-10: MAVYRET (NDA209394 SUPPL19) |
| 2025-06-10 | FDA approval | approved | CYCLE | HARLIKU; NITYR | Approved 2025-06-10: HARLIKU; NITYR (NDA209449 SUPPL18) |
| 2025-06-11 | FDA approval | approved | NUVATION NUVB | IBTROZI | Approved 2025-06-11: IBTROZI (NDA219713 ORIG1) |
| 2025-06-11 | FDA approval | approved | SANOFI SNY | HECTOROL | Approved 2025-06-11: HECTOROL (NDA020862 SUPPL33) |
| 2025-06-12 | FDA approval | approved | PFIZER PFE | TALZENNA | Approved 2025-06-12: TALZENNA (NDA217439 SUPPL3) |
| 2025-06-12 | FDA approval | approved | PFIZER PFE | TALZENNA | Approved 2025-06-12: TALZENNA (NDA211651 SUPPL13) |
| 2025-06-12 | FDA approval | approved | UROGEN PHARMA URGN | ZUSDURI | Approved 2025-06-12: ZUSDURI (NDA215793 ORIG1) |
| 2025-06-12 | FDA approval | approved | MERCK SHARP DOHME MRK | KEYTRUDA | Approved 2025-06-12: KEYTRUDA (BLA125514 SUPPL180) |
| 2025-06-16 | FDA approval | approved | AZURITY | ARYNTA | Approved 2025-06-16: ARYNTA (NDA219847 ORIG1) |
| 2025-06-16 | FDA approval | approved | GENERAL DISTRIBUTING COMPANY | CARBON DIOXIDE USP | Approved 2025-06-16: CARBON DIOXIDE, USP (NDA220634 ORIG1) |
| 2025-06-16 | FDA approval | approved | CSL BEHRING LLC | ANDEMBRY | Approved 2025-06-16: ANDEMBRY (BLA761367 ORIG1) |
| 2025-06-18 | FDA approval | approved | GLAXOSMITHKLINE | ZEJULA | Approved 2025-06-18: ZEJULA (NDA214876 SUPPL3) |
| 2025-06-18 | FDA approval | approved | MORPHOSYS US INC | MONJUVI | Approved 2025-06-18: MONJUVI (BLA761163 SUPPL13) |
| 2025-06-18 | FDA approval | approved | GILEAD SCIENCES INC GILD | YEZTUGO | Approved 2025-06-18: YEZTUGO (NDA220018 ORIG1) |
| 2025-06-18 | FDA approval | approved | GILEAD SCIENCES INC GILD | YEZTUGO | Approved 2025-06-18: YEZTUGO (NDA220020 ORIG1) |
| 2025-06-18 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | DUPIXENT | Approved 2025-06-18: DUPIXENT (BLA761055 SUPPL70) |
| 2025-06-20 | Complete response letter | complete response | Cipla USA, Inc. | CRL 2025-06-20: Cipla USA, Inc. NDA 210168 | |
| 2025-06-20 | FDA approval | approved | GILEAD SCIENCES INC GILD | DESCOVY | Approved 2025-06-20: DESCOVY (NDA208215 SUPPL25) |
| 2025-06-20 | FDA approval | approved | GILEAD SCIENCES INC GILD | DESCOVY | Approved 2025-06-20: DESCOVY (NDA208215 SUPPL23) |
| 2025-06-20 | FDA approval | approved | GILEAD SCIENCES INC GILD | TYBOST | Approved 2025-06-20: TYBOST (NDA203094 SUPPL17) |
| 2025-06-20 | FDA approval | approved | GILEAD SCIENCES INC GILD | TYBOST | Approved 2025-06-20: TYBOST (NDA203094 SUPPL18) |
| 2025-06-20 | FDA approval | approved | GLAXOSMITHKLINE LLC | BENLYSTA | Approved 2025-06-20: BENLYSTA (BLA761043 SUPPL34) |
| 2025-06-23 | FDA approval | approved | AVID RADIOPHARMS INC | AMYVID | Approved 2025-06-23: AMYVID (NDA202008 SUPPL46) |
| 2025-06-23 | FDA approval | approved | GE HEALTHCARE | VIZAMYL | Approved 2025-06-23: VIZAMYL (NDA203137 SUPPL24) |
| 2025-06-23 | FDA approval | approved | LANTHEUS LNTH | NEURACEQ | Approved 2025-06-23: NEURACEQ (NDA204677 SUPPL24) |
| 2025-06-23 | FDA approval | approved | DAIICHI SANKYO INC | DATROWAY | Approved 2025-06-23: DATROWAY (BLA761464 ORIG1) |
| 2025-06-25 | Complete response letter | complete response | Sun Pharmaceutical Industries Limited | (nilotinib) capsules | CRL 2025-06-25: Sun Pharmaceutical Industries Limited NDA 215644 ((nilotinib) capsules) |
| 2025-06-26 | Complete response letter | complete response | Accord BioPharma Inc. | INTP1 | CRL 2025-06-26: Accord BioPharma Inc. BLA 761027 (INTP1) |
| 2025-06-27 | Complete response letter | complete response | Unicycive Therapeutics Inc. UNCY | oxylanthanum carbonate | CRL 2025-06-27: Unicycive Therapeutics Inc. NDA 218607 (oxylanthanum carbonate tablets) |
| 2025-06-27 | FDA approval | approved | AVYXA HOLDINGS | AVGEMSI | Approved 2025-06-27: AVGEMSI (NDA219920 ORIG1) |
| 2025-06-27 | FDA approval | approved | HIKMA | TYZAVAN | Approved 2025-06-27: TYZAVAN (NDA211962 SUPPL17) |
| 2025-06-27 | FDA approval | approved | APRECIA PHARMS | SPRITAM | Approved 2025-06-27: SPRITAM (NDA207958 SUPPL27) |
| 2025-06-27 | FDA approval | approved | NOVIMMUNE S.A. | GAMIFANT | Approved 2025-06-27: GAMIFANT (BLA761107 SUPPL18) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-06 est. | P2 | Newish Technology (Beijing) Co., Ltd. | NCT03820310 Clinical Trial of Autologous Tcm Immunotherapy in ICC | Cholangiocarcinoma | unknown | 20 |
| 2025-06 est. | P2 | RedHill Biopharma Limited RDHL | NCT04026984 Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years | Traveler's Diarrhea | unknown | 142 |
| 2025-06 est. | P2/P3 | Advicenne Pharma | NCT04137978 Study Evaluating Patients With Cystinuria | Cystinuria | withdrawn | |
| 2025-06 est. | P1/P2 | Foresee Pharmaceuticals Co., Ltd. | NCT04522375 A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia | Fanconi Anemia | withdrawn | |
| 2025-06 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04523272 A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer | Advanced Renal Cancer | unknown | 528 |
| 2025-06 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT04818333 A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | unknown | 157 |
| 2025-06 est. | P3 | Cyclo Therapeutics, Inc. | NCT04860960 Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1 | Niemann-Pick Disease, Type C1 | unknown | 94 |
| 2025-06 est. | P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT04971551 A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. | Acute Graft-Versus-Host Disease | unknown | 60 |
| 2025-06 est. | P3 | Ascletis Pharmaceuticals Co., Ltd. | NCT05118776 Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | Recurrent Glioblastoma | unknown | 136 |
| 2025-06 est. | P3 | Amzell | NCT05128344 A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms | Spasms, Infantile | withdrawn | |
| 2025-06 est. | P1/P2 | Nuvation Bio Inc. NUVB | NCT05191004 Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Bre | withdrawn | |
| 2025-06 est. | P3 | Evopoint Biosciences Inc. | NCT05204368 Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (Eud | Complicated Urinary Tract Infection Including Acute Pyelonephritis | unknown | 780 |
| 2025-06 est. | P1/P2 | Binhui Biopharmaceutical Co., Ltd. | NCT05232136 OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer | Non-muscle-invasive Bladder Cancer | unknown | 30 |
| 2025-06 est. | P2 | Green Cross Corporation | NCT05422508 Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccina | Varicella | recruiting | 230 |
| 2025-06 est. | P3 | Aytu BioPharma, Inc. AYTU | NCT05463679 Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. | Vascular Ehlers-Danlos Syndrome | suspended | 260 |
| 2025-06 est. | P3 | Guangzhou Gloria Biosciences Co., Ltd. | NCT05518318 GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) | Classic Hodgkin's Lymphoma; Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma | unknown | 60 |
| 2025-06 est. | P1/P2 | Kartos Therapeutics, Inc. | NCT05705466 Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | withdrawn | |
| 2025-06 est. | P2 | Akeso | NCT05859750 A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | Pancreatic Cancer | recruiting | 78 |
| 2025-06 est. | P2 | EverImmune | NCT05865730 A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung | unknown | 122 |
| 2025-06 est. | P3 | FutureChem | NCT05936658 [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer | High Risk Prostate Carcinoma | active not recruiting | 138 |
| 2025-06 est. | P3 | ISU Abxis Co., Ltd. | NCT06081062 Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease | Fabry Disease | unknown | 24 |
| 2025-06 est. | P2 | ReAlta Life Sciences, Inc. | NCT06175065 Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Acute Exacerbation of Chronic Obstructive Pulmonary Disease | active not recruiting | 24 |
| 2025-06 est. | P3 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT06216392 Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis | Atopic Dermatitis | unknown | 450 |
| 2025-06 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06218771 A Study of TQB3454 Tablets in Patients With Blood Tumors | Acute Myeloid Leukemia; Myelodysplastic Syndromes | unknown | 80 |
| 2025-06 est. | P3 | Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica | NCT06296212 Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia. | Pneumonia; Myocardial Injury | unknown | 178 |
| 2025-06 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06361927 A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients | NSCLC | unknown | 120 |
| 2025-06 est. | P3 | Boston Medical Group | NCT06425224 Effectiveness and Safety of TENS Therapy for Premature Ejaculation | Premature Ejaculation; Sex Disorder; TEN | recruiting | 129 |
| 2025-06 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06493760 A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | Metastatic Colorectal Cancer | recruiting | 130 |
| 2025-06 est. | P2 | OrsoBio, Inc | NCT06564584 Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD | Hypertriglyceridemia; Nonalcoholic Fatty Liver Disease | unknown | 30 |
| 2025-06 est. | P3 | Jina Pharmaceuticals Inc. | NCT06608641 Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients | Bipolar 1 Disorder | unknown | 490 |
| 2025-06 est. | P2 | Shandong New Time Pharmaceutical Co., LTD | NCT06782594 A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction | Postoperative Gastrointestinal Dysfunction | unknown | 150 |
| 2025-06 est. | P1/P2 | Ace Cells Lab Limited | NCT06787482 Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies | Retinitis Pigmentosa (RP); Age Related Macular Degeneration; Diabetic Retinopathy | recruiting | 100 |
| 2025-06 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06957379 Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard | HR+/HER2- Advanced/Metastatic Breast Cancer | active not recruiting | 78 |
| 2025-06-01 | P3 | EMS | NCT02483936 Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control | Arterial Hypertension | withdrawn | |
| 2025-06-01 | P3 | EMS | NCT02493322 Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control | Essential Arterial Hypertension | withdrawn | |
| 2025-06-01 est. | P1/P2 | CARsgen Therapeutics Co., Ltd. | NCT04404595 Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | Gastric Cancer; Pancreatic Cancer | active not recruiting | 110 |
| 2025-06-01 est. | P3 | FutureChem | NCT05004285 Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis | High Risk Prostate Carcinoma | active not recruiting | 398 |
| 2025-06-01 est. | P3 | Betta Pharmaceuticals Co., Ltd. | NCT05341583 Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | unknown | 202 |
| 2025-06-01 est. | P1/P2 | FutureChem | NCT05458544 [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application | Metastatic Castration-resistant Prostate Cancer | unknown | 26 |
| 2025-06-01 est. | P1/P2 | Ranok Therapeutics (Hangzhou) Co., Ltd. | NCT05487170 A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | Advanced Solid Tumor; DLBCL | recruiting | 32 |
| 2025-06-01 est. | P1/P2 | TYK Medicines, Inc | NCT05675605 A Study of TY-1091 in Patients With Advanced Solid Tumors | RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Canc | unknown | 248 |
| 2025-06-01 est. | P1/P2 | Tyligand Bioscience (Shanghai) Limited | NCT05842785 TSN222 in Subjects With Advanced Solid Tumors or Lymphomas | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | unknown | 162 |
| 2025-06-01 est. | P3 | Genuine Research Center, Egypt | NCT05876585 Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vo | Gastroenteritis | unknown | 126 |
| 2025-06-01 est. | P2 | Oticara Australia PTY LTD | NCT05882903 The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery | Chronic Rhinosinusitis (Diagnosis) | recruiting | 24 |
| 2025-06-01 est. | P2 | Lipella Pharmaceuticals, Inc. LIPO | NCT06233591 Evaluating LP-10 in Subjects With OLP | Oral Lichen Planus | unknown | 24 |
| 2025-06-01 est. | P2 | RemeGen Co., Ltd. | NCT06389006 To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive | Breast Cancer | recruiting | 79 |
| 2025-06-01 est. | P3 | Beijing Minhai Biotechnology Co., Ltd | NCT06608199 A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine | Pneumococcal Vaccines; Pneumococcal Infections | recruiting | 500 |
| 2025-06-02 | P2 | Regeneron Pharmaceuticals REGN | NCT05353166 REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure | Heart Failure | completed | 59 |
| 2025-06-02 | P2 | Osivax | NCT06582277 Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836 | Vaccine-Preventable Diseases; Influenza | completed | 117 |
| 2025-06-02 | P2 | Dryox Health | NCT06645509 Severe Primary Hand Hyperhidrosis Treatment With Topical Administration of Victorhy | Palmar Hyperhidrosis | terminated | 58 |
| 2025-06-02 | P2 | Cerus Corporation CERS | NCT06697223 A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator | Healthy Subjects | completed | 40 |
| 2025-06-03 | P2/P3 | Acacia Pharma Ltd | NCT05546359 Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients | Nausea and Vomiting, Postoperative | completed | 453 |
| 2025-06-03 | P3 | Takeda TAK | NCT06470828 A Study of TAK-861 for the Treatment of Narcolepsy Type 1 | Narcolepsy Type 1 | completed | 168 |
| 2025-06-03 | P3 | GlaxoSmithKline | NCT06614725 A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age a | Respiratory Syncytial Virus Infections | completed | 751 |
| 2025-06-03 | P3 | HTA Co., Ltd. | NCT07764653 Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer | Sentinel Nodes; Breast Cancer | completed | 213 |
| 2025-06-04 | P3 | Sun Pharmaceutical Industries Limited | NCT04314531 Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | Active Psoriatic Arthritis | active not recruiting | 296 |
| 2025-06-04 | P2 | Esperion Therapeutics, Inc. | NCT05694260 A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path | Hypercholesterolemia | completed | 31 |
| 2025-06-04 | P2 | Celldex Therapeutics CLDX | NCT05774184 A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | completed | 86 |
| 2025-06-04 | P3 | Takeda TAK | NCT06505031 A Study of TAK-861 in People With Narcolepsy Type 1 | Narcolepsy Type 1 | completed | 105 |
| 2025-06-04 | P2 | AstraZeneca AZN | NCT06644924 A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma | Asthma | completed | 118 |
| 2025-06-05 | P3 | AbbVie ABBV | NCT04166058 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C | Irritable Bowel Syndrome With Constipation; Functional Constipation | completed | 381 |
| 2025-06-05 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT04571710 A Trial of SHR1258 in Patients With Biliary Tract Cancer | Biliary Tract Cancer | withdrawn | |
| 2025-06-05 | P2/P3 | GlaxoSmithKline | NCT04655976 Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cance | Lung Cancer, Non-Small Cell | active not recruiting | 758 |
| 2025-06-05 | P2 | Pfizer PFE | NCT05879718 A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. | Lupus Erythematosus, Systemic; Lupus Erythematosus, Cutaneous | terminated | 8 |
| 2025-06-05 | P3 | Eli Lilly and Company LLY | NCT06010004 A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | Type 2 Diabetes | completed | 401 |
| 2025-06-05 | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06012812 A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | completed | 79 |
| 2025-06-05 | P2 | Jetema USA Inc. | NCT06246552 Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines | Glabellar Lines | completed | 480 |
| 2025-06-05 | P3 | Vigonvita Life Sciences | NCT06301854 Long-term Safety of TPN171H Tablet in Erectile Dysfunction. | Erectile Dysfunction | completed | 472 |
| 2025-06-06 | P3 | Merck Sharp & Dohme LLC MRK | NCT03924895 Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Particip | Urinary Bladder Cancer, Muscle-invasive | active not recruiting | 595 |
| 2025-06-06 | P3 | Biocad | NCT05802225 Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer | Breast Cancer | active not recruiting | 398 |
| 2025-06-06 | P1/P2 | Incyte Corporation INCY | NCT05949632 A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | Advanced Solid Tumors | terminated | 5 |
| 2025-06-06 | P1/P2 | Tasly Pharmaceutical Group Co., Ltd | NCT06238687 A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors | Neoplasm Malignant | completed | 19 |
| 2025-06-06 | P2 | Clexio Biosciences Ltd. | NCT06340958 A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder | Adjunctive Treatment of Major Depressive Disorder (MDD) | completed | 99 |
| 2025-06-09 | P3 | AbbVie ABBV | NCT04064827 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With S | Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism (SHPT) | terminated | 2 |
| 2025-06-09 | P3 | Hoffmann-La Roche | NCT05123703 A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RR | Relapsing-remitting Multiple Sclerosis | active not recruiting | 188 |
| 2025-06-09 | P2 | AbbVie ABBV | NCT05760313 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treate | Functional Constipation | completed | 19 |
| 2025-06-09 | P3 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05861102 Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) | Ankylosing Spondylitis | completed | 265 |
| 2025-06-09 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06361875 A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above | Influenza Immunization; Healthy Volunteers | completed | 908 |
| 2025-06-09 | P2 | Shijiazhuang Yiling Pharmaceutical Co. Ltd | NCT06755944 A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke | Stroke, Ischemic | completed | 360 |
| 2025-06-10 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04906993 Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | Cervical Cancer | active not recruiting | 443 |
| 2025-06-10 | P2 | Xencor, Inc. XNCR | NCT05005728 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | completed | 72 |
| 2025-06-10 | P1/P2 | Sixera Pharma | NCT05211830 A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome | Netherton Syndrome | completed | 9 |
| 2025-06-10 | P3 | Ahn-Gook Pharmaceuticals Co.,Ltd | NCT05503953 Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS | Essential Hypertension | completed | 318 |
| 2025-06-10 | P2 | Eli Lilly and Company LLY | NCT06901349 A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | Obesity; Overweight | withdrawn | |
| 2025-06-11 | P3 | Sanofi SNY | NCT02859896 Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis | Secondary Hyperparathyroidism-Chronic Kidney Disease | terminated | 21 |
| 2025-06-11 | P2 | Nuvation Bio Inc. NUVB | NCT04919811 Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Non Small Cell Lung Cancer | active not recruiting | 217 |
| 2025-06-11 | P2 | Hoffmann-La Roche | NCT05075824 A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE | Sickle Cell Disease | completed | 95 |
| 2025-06-11 est. | P3 | Shanghai Mabgeek Biotech.Co.Ltd | NCT06026891 Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis | Atopic Dermatitis | unknown | 498 |
| 2025-06-11 | P2 | Eli Lilly and Company LLY | NCT06074562 A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy | completed | 404 |
| 2025-06-11 | P3 | Pfizer PFE | NCT06325657 A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants | Respiratory Syncytial Virus | completed | 681 |
| 2025-06-11 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06705140 A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers | RSV Immunisation; Healthy Volunteers | terminated | 42 |
| 2025-06-11 | P1/P2 | Genmab GMAB | NCT06771921 A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | Malignant Solid Tumor | terminated | 3 |
| 2025-06-12 | P3 | Eli Lilly and Company LLY | NCT04255433 A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | completed | 13299 |
| 2025-06-12 | P1/P2 | GlaxoSmithKline | NCT05298254 A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Part | Herpes Simplex | completed | 504 |
| 2025-06-12 est. | P2 | Shanghai Jiatan Pharmatech Co., Ltd | NCT06117540 A Study of WX390 in Patients With Advanced Solid Tumors | Solid Tumor | unknown | 70 |
| 2025-06-13 | P2/P3 | Gilead Sciences GILD | NCT02016924 Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV | Acquired Immune Deficiency Syndrome (AIDS); HIV Infections | active not recruiting | 133 |
| 2025-06-13 | P2 | Merck Sharp & Dohme LLC MRK | NCT03516981 A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | Advanced Non-Small Cell Lung Cancer | completed | 245 |
| 2025-06-13 | P1/P2 | Repare Therapeutics | NCT04497116 Study of RP-3500, Camonsertib, in Advanced Solid Tumors | Advanced Solid Tumor | completed | 276 |
| 2025-06-13 | P1/P2 | Sanofi SNY | NCT05086315 First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-ce | Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndromes; Blastic | terminated | 101 |
| 2025-06-13 | P2 | iTeos Therapeutics | NCT05403385 Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung Cancer; Locally Advanced NSCLC - Non-Small Cell Lung Cancer | active not recruiting | 36 |
| 2025-06-13 | P3 | Click Therapeutics, Inc. CLIK | NCT06067984 An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia | Schizophrenia; Negative Symptoms in Schizophrenia | completed | 73 |
| 2025-06-13 | P3 | Shenzhen HighTide Biopharmaceutical Ltd. | NCT06415773 Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin | T2DM (Type 2 Diabetes Mellitus) | completed | 367 |
| 2025-06-13 | P1/P2 | Arcturus Therapeutics, Inc. ARCT | NCT06602531 Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults | Influenza, Human | completed | 212 |
| 2025-06-13 | P3 | Zhejiang Huahai Pharmaceutical Co., Ltd. | NCT07253207 Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder | Major Depressive Disorder (MDD) | completed | 392 |
| 2025-06-15 | P3 | Hoffmann-La Roche | NCT04660344 A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following | Muscle-invasive Bladder Cancer | completed | 761 |
| 2025-06-15 est. | P3 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT05673590 Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | unknown | 612 |
| 2025-06-15 est. | P3 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT05673629 Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer | Breast Cancer | unknown | 552 |
| 2025-06-15 | P2/P3 | Quit Genius | NCT05748639 Integrated Digital Intervention for Alcohol Use Disorder | Alcohol Use Disorder | completed | 242 |
| 2025-06-15 est. | P2 | Apex Labs Ltd. | NCT06141876 Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD | Post-traumatic Stress Disorder; Depression | unknown | 160 |
| 2025-06-15 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT06394713 A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors | Advanced Malignant Neoplasm | not yet recruiting | 60 |
| 2025-06-16 | P2 | Axalbion SA | NCT04866563 A Study of Efficacy and Safety of AX-8 in Chronic Cough | Chronic Cough | completed | 108 |
| 2025-06-16 | P3 | Braintree Laboratories | NCT05587309 A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis | Erosive Esophagitis | completed | 1250 |
| 2025-06-16 | P3 | AstraZeneca AZN | NCT05943106 BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants | Non-Muscle- Invasive Bladder Cancer | active not recruiting | 100 |
| 2025-06-16 | P2/P3 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | NCT06083623 A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants | Respiratory Syncytial Virus Infections | completed | 2282 |
| 2025-06-16 | P2 | Genentech, Inc. | NCT06137183 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) | Ulcerative Colitis | terminated | 79 |
| 2025-06-16 | P2 | Vigonvita Life Sciences | NCT06206720 A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV | Respiratory Syncytial Virus Infection | completed | 60 |
| 2025-06-17 | P1/P2 | Takeda TAK | NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Squamous Cell Cancer of Head and Neck (SCCHN); Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer | terminated | 95 |
| 2025-06-17 | P2 | Kite, A Gilead Company | NCT04880434 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | Relapsed/Refractory Mantle Cell Lymphoma | completed | 95 |
| 2025-06-17 | P2 | Metro International Biotech, LLC | NCT05878119 Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program | Healthy | completed | 124 |
| 2025-06-17 | P2 | BeiGene | NCT05909904 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer | completed | 160 |
| 2025-06-17 | P3 | Renibus Therapeutics, Inc. | NCT06021457 Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery | Post-Operative Complications in Cardiac Surgery | completed | 454 |
| 2025-06-17 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT06242691 Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) | Advanced Solid Tumors | completed | 13 |
| 2025-06-17 | P3 | Immedica Pharma AB | NCT06582524 Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency | Arginase 1 Deficiency | completed | 3 |
| 2025-06-18 | P3 | CStone Pharmaceuticals | NCT04194775 A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | active not recruiting | 534 |
| 2025-06-18 | P3 | Capricor Inc. CAPR | NCT05126758 A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic; Muscular Diseases; | active not recruiting | 106 |
| 2025-06-18 | P1/P2 | Xindu Pty Ltd | NCT05344157 A First-in-Human Study of XSTEM-OA in Patients With Knee Osteoarthritis | Osteoarthritis, Knee | completed | 24 |
| 2025-06-18 | P2 | Sanofi SNY | NCT06073093 A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis | Rheumatoid Arthritis | completed | 264 |
| 2025-06-18 | P3 | Hanmi Pharmaceutical Company Limited HAFC | NCT06595004 A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients | Chronic Low-back Pain | completed | 310 |
| 2025-06-18 | P2 | Aldeyra Therapeutics, Inc. ALDX | NCT06685692 A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) | Alcohol Hepatitis | completed | 4 |
| 2025-06-19 | P3 | Merz Pharmaceuticals GmbH | NCT03992404 Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain | Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury | active not recruiting | 603 |
| 2025-06-19 | P2 | Archivel Farma S.L. | NCT04919239 Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) | Tuberculosis, Pulmonary | completed | 140 |
| 2025-06-19 | P3 | Rose Research Center, LLC | NCT05205811 The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette | Smoking Cessation | completed | 180 |
| 2025-06-19 | P3 | Novartis Pharmaceuticals NVS | NCT05653219 A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids | Primary Immune Thrombocytopenia | active not recruiting | 152 |
| 2025-06-19 | P3 | Eli Lilly and Company LLY | NCT05931380 A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | Obesity | completed | 238 |
| 2025-06-19 | P2 | Alnylam Pharmaceuticals ALNY | NCT06272487 Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medicati | High Cardiovascular Risk; Hypertension | completed | 375 |
| 2025-06-19 | P2 | Alkermes, Inc. ALKS | NCT06358950 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) | Narcolepsy Type 1 | completed | 92 |
| 2025-06-19 | P2 | Procter and Gamble PG | NCT06892834 Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control. | Gingivitis | completed | 120 |
| 2025-06-19 | P3 | Medprin Regenerative Medical Technologies Co., Ltd. | NCT07754344 Dural Medical Adhesive for Watertight Sealing in Dural Repair | Spinal Dural Defect; Cerebrospinal Fluid Leakage; Spinal Neurosurgery | completed | 141 |
| 2025-06-20 | P2 | Mapi Pharma Ltd. | NCT03362294 Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS | Primary Progressive Multiple Sclerosis | terminated | 30 |
| 2025-06-20 | P1/P2 | Nacuity Pharmaceuticals, Inc. | NCT04355689 Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome | Usher Syndromes | completed | 49 |
| 2025-06-20 | P3 | Hansa Biopharma AB | NCT04935177 Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx | Kidney Transplantation in Highly Sensitized Patients | completed | 64 |
| 2025-06-20 | P3 | Amgen AMGN | NCT05052801 Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | completed | 547 |
| 2025-06-20 | P2 | EMD Serono Research & Development Institute, Inc. | NCT05327530 A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley | Locally Advanced or Metastatic Urothelial Carcinoma | active not recruiting | 256 |
| 2025-06-20 | P3 | Click Therapeutics, Inc. CLIK | NCT05838625 Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia | Schizophrenia | completed | 464 |
| 2025-06-20 | P3 | CSL Behring | NCT06524739 Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS | Post-COVID Postural Orthostatic Tachycardia Syndrome | terminated | 16 |
| 2025-06-23 | P2 | Merck Sharp & Dohme LLC MRK | NCT04924101 Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Can | Small Cell Lung Cancer | completed | 122 |
| 2025-06-23 | P2 | Enanta Pharmaceuticals, Inc ENTA | NCT05568706 A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. | RSV Infection | completed | 187 |
| 2025-06-23 | P3 | Hansa Biopharma AB | NCT05679401 A Study With Imlifidase in Anti-GBM Disease | Anti-Glomerular Basement Membrane Disease; Anti-Glomerular Basement Membrane Antibody Disease; Goodp | terminated | 50 |
| 2025-06-23 est. | P3 | Lipogems International spa | NCT06121882 Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis | Knee Osteoarthritis; Osteo Arthritis Knee | active not recruiting | 173 |
| 2025-06-23 | P2 | Engrail Therapeutics INC | NCT06653296 A Dose-Response Safety Study of ENX-102 in Patients With GAD | General Anxiety Disorder | completed | 38 |
| 2025-06-23 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07253584 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Th | Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia | completed | 720 |
| 2025-06-24 | P1/P2 | Cybrexa Therapeutics | NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | Solid Tumor, Adult; Epithelial Ovarian Cancer; Small Cell Lung Carcinoma; Breast Cancer; Colorectal | completed | 69 |
| 2025-06-24 | P1/P2 | GlaxoSmithKline | NCT05073003 A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants | Diarrhoea | completed | 551 |
| 2025-06-24 | P3 | Abivax S.A. ABVX | NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | Ulcerative Colitis | completed | 639 |
| 2025-06-24 | P3 | Abivax S.A. ABVX | NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 | Ulcerative Colitis | completed | 636 |
| 2025-06-24 | P3 | Hoffmann-La Roche | NCT05595642 A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease (COPD) | completed | 1380 |
| 2025-06-24 | P2 | Innostellar Biotherapeutics Co.,Ltd | NCT06196840 Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) | Neovascular Age-Related Macular Degeneration | active not recruiting | 50 |
| 2025-06-24 | P1/P2 | Asahi Kasei Therapeutics, AB | NCT06274489 A Study to Evaluate Setanaxib in Patients With Alport Syndrome | Alport Syndrome | completed | 20 |
| 2025-06-24 | P2 | TORQUR | NCT06319794 Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis | Actinic Keratosis | completed | 46 |
| 2025-06-24 | P2 | Viking Therapeutics, Inc. VKTX | NCT06828055 VK2735 for Weight Management Phase 2 (Venture Oral Dosing) | Weight Loss | completed | 280 |
| 2025-06-25 | P1/P2 | Hangzhou Hanx Biopharmaceuticals, Ltd. | NCT05189093 Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma | Relapsed/Refractory Lymphoma | completed | 48 |
| 2025-06-25 | P3 | aTyr Pharma, Inc. ATYR | NCT05415137 Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | completed | 268 |
| 2025-06-25 | P2 | AbbVie ABBV | NCT05443724 A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | Schizophrenia | terminated | 698 |
| 2025-06-25 | P2 | EMD Serono Research & Development Institute, Inc. | NCT05650567 Study of M5049 in DM and PM Participants (NEPTUNIA) | Dermatomyositis; Polymyositis | terminated | 20 |
| 2025-06-25 | P3 | Almirall, S.A. | NCT05990725 Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis; Eczema | completed | 260 |
| 2025-06-25 est. | P3 | Tasly Pharmaceutical Group Co., Ltd | NCT06697886 A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold | Common Cold | recruiting | 480 |
| 2025-06-25 | P3 | Celltrion | NCT06738719 A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis | Moderately to Severely Active Rheumatoid Arthritis | completed | 192 |
| 2025-06-26 | P2 | Ionis Pharmaceuticals, Inc. IONS | NCT05143957 A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera | Phlebotomy Dependent Polycythemia Vera | completed | 50 |
| 2025-06-26 | P3 | Sinotau Pharmaceutical Group | NCT05459844 A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | Neuroendocrine Tumors | completed | 196 |
| 2025-06-26 | P2 | Ryan Dackor | NCT05617313 Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer; Metastatic NSCLC; Recurrent Non Small Cell Lung Cancer | terminated | 21 |
| 2025-06-26 | P2 | Kowa Research Institute, Inc. | NCT06247735 Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycho | Primary Biliary Cholangitis | completed | 46 |
| 2025-06-26 | P2 | J2H Biotech | NCT06297434 Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH | Non-alcoholic Steatohepatitis | completed | 87 |
| 2025-06-27 est. | P2 | Leadiant Biosciences, Inc. | NCT04231266 Multi-Center Study of ManNAc for GNE Myopathy | GNE Myopathy | active not recruiting | 54 |
| 2025-06-27 | P2 | Allist Pharmaceuticals, Inc. | NCT05466149 Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion | NSCLC | active not recruiting | 100 |
| 2025-06-27 | P3 | Novartis Pharmaceuticals NVS | NCT05842954 Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria | Uncomplicated Plasmodium Falciparum Malaria | completed | 1720 |
| 2025-06-27 | P2 | ModernaTX, Inc. | NCT06097299 A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | Respiratory Syncytial Virus | completed | 349 |
| 2025-06-27 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06164873 A Study of IBI362 9 mg in Chinese Adults With Obesity | Obesity | unknown | 462 |
| 2025-06-27 | P2 | Merck Sharp & Dohme LLC MRK | NCT06482112 Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) | Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-alcoholic Fatty Liver Disease; Nonalco | completed | 124 |
| 2025-06-27 | P2 | Manistee Therapeutics | NCT06728553 Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults | Migraine | completed | 78 |
| 2025-06-29 | P3 | Bausch & Lomb Incorporated BLCO | NCT06803654 A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With O | Ocular Redness | completed | 578 |
| 2025-06-30 | P1/P2 | eyeDNA Therapeutics | NCT03328130 Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene | Retinitis Pigmentosa | terminated | 19 |
| 2025-06-30 | P3 | Hoffmann-La Roche | NCT04548999 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | Multiple Sclerosis | active not recruiting | 769 |
| 2025-06-30 est. | P2 | Telios Pharma, Inc. | NCT04655118 Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | Myelofibrosis; Indolent Systemic Mastocytosis | unknown | 121 |
| 2025-06-30 est. | P1/P2 | Simcha IL-18, Inc. | NCT04787042 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Cancer; Solid Tumor; Melanoma; Renal Cell Carcinoma; Triple-negative Breast Cancer; Non Small Cell L | recruiting | 316 |
| 2025-06-30 | P1/P2 | Genmab GMAB | NCT04824794 GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | Relapsed or Refractory Multiple Myeloma (RRMM); Diffuse Large B Cell Lymphoma (DLBCL); Acute Myeloid | terminated | 130 |
| 2025-06-30 | P1/P2 | Shanghai Escugen Biotechnology Co., Ltd | NCT04892342 Study of ESG401 in Adults With Solid Tumors | Neoplasms, Breast; Neoplasms, Lung; Neoplasms,Colorectal; Neoplasms, Bladder; Neoplasm of Stomach; N | completed | 156 |
| 2025-06-30 | P3 | AstraZeneca AZN | NCT04964934 Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | ER-Positive HER2-Negative Breast Cancer | active not recruiting | 315 |
| 2025-06-30 | P2 | Pharvaris Netherlands B.V. PHVS | NCT05047185 Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II | Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angio | terminated | 34 |
| 2025-06-30 | P3 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05051891 A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Predniso | Treatment-naїve Mantle Cell Lymphoma | completed | 3 |
| 2025-06-30 | P2 | Recursion Pharmaceuticals Inc. RXRX | NCT05085561 The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 | Cerebral Cavernous Malformation | completed | 62 |
| 2025-06-30 | P3 | United Therapeutics UTHR | NCT05255991 Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | 597 |
| 2025-06-30 | P3 | Fresenius Medical Care North America FMS | NCT05339139 SAfety of Regional Citrate Anticoagulation (SARCA Study) | Acute Kidney Injury; ESRD | completed | 32 |
| 2025-06-30 | P2 | Coherus Oncology, Inc. CHRS | NCT05359861 Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma | Hepatocellular Carcinoma | terminated | 30 |
| 2025-06-30 | P1/P2 | SwanBio Therapeutics, Inc. | NCT05394064 A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) | AMN; AMN Gene Mutation; X-ALD | terminated | 9 |
| 2025-06-30 | P3 | PharmaEssentia | NCT05481151 A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | Polycythemia Vera | active not recruiting | 111 |
| 2025-06-30 | P2 | SOFIE | NCT05641896 Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers | Gastrointestinal Cancers; Cholangiocarcinoma; Gastric Cancer; Colorectal Cancer; Pancreatic Ductal A | completed | 112 |
| 2025-06-30 | P1/P2 | Syndax Pharmaceuticals SNDX | NCT05731947 Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | Colorectal Cancer; Solid Tumors | terminated | 41 |
| 2025-06-30 est. | P3 | Fosun Adgenvax Biopharmaceutical Co.,Ltd. | NCT05759520 Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants | Streptococcus Pneumoniae Infection | unknown | 1800 |
| 2025-06-30 est. | P1/P2 | Coherent Biopharma (Hefei) Co., Ltd. COHR | NCT05830097 A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | Cancer, Breast; Cancer, Lung; Cancer of Pancreas; Cancer of Esophagus; Cancer Colorectal | unknown | 260 |
| 2025-06-30 | P2 | Novartis Pharmaceuticals NVS | NCT05834738 Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy | IgA Nephropathy; Immunoglobulin A Nephropathy | completed | 54 |
| 2025-06-30 est. | P2 | Neuren Pharmaceuticals Limited | NCT05879614 An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) | Prader-Willi Syndrome | withdrawn | |
| 2025-06-30 est. | P2 | WestVac Biopharma Co., Ltd. | NCT05911048 A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination | COVID-19 | unknown | 3100 |
| 2025-06-30 est. | P3 | WestVac Biopharma Co., Ltd. | NCT05911061 A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination | COVID-19 | unknown | 4950 |
| 2025-06-30 est. | P2 | NorthSea Therapeutics B.V. | NCT05919680 A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). | Intestinal Failure Associated Liver Disease | recruiting | 36 |
| 2025-06-30 | P2 | NiKang Therapeutics, Inc. | NCT05935748 Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | ccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplas | terminated | 18 |
| 2025-06-30 est. | P2 | Hansoh BioMedical R&D Company | NCT06052423 ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | withdrawn | |
| 2025-06-30 est. | P2 | Beijing Yongtai Ruike Biotechnology Company Ltd | NCT06179524 CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia | recruiting | 100 |
| 2025-06-30 est. | P2 | Convalife (Shanghai) Co., Ltd. | NCT06183736 CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency | Advanced Solid Tumors | not yet recruiting | 98 |
| 2025-06-30 est. | P2 | Anavex Life Sciences Corp. AVXL | NCT06245213 A Study of ANAVEX3-71 in Adults With Schizophrenia | Schizophrenia | active not recruiting | 71 |
| 2025-06-30 | P2 | Ryvu Therapeutics SA | NCT06268574 Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML | Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome | terminated | 62 |
| 2025-06-30 | P3 | argenx ARGX | NCT06298552 A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthe | Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized; Myasthenia Gravis | active not recruiting | 119 |
| 2025-06-30 est. | P2 | AmtixBio Co., Ltd. | NCT06327295 A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis | Onychomycosis | recruiting | 120 |
| 2025-06-30 est. | P1/P2 | Norroy Bioscience Co., LTD | NCT06383052 A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | Metastatic Castration-resistant Prostate Cancer | active not recruiting | 30 |
| 2025-06-30 est. | P2 | Hansoh BioMedical R&D Company | NCT06393673 A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women | Vasomotor Symptoms | unknown | 195 |
| 2025-06-30 | P3 | Taizhou Mabtech Pharmaceutical Co.,Ltd | NCT06398652 Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis | Psoriasis | completed | 336 |
| 2025-06-30 est. | P1/P2 | YolTech Therapeutics Co., Ltd | NCT06539208 A Phase I/IIa,Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of | Transthyretin Amyloidosis Polyneuropathy; Transthyrexin Amyloidosis Cardiomyopathy | unknown | 31 |
| 2025-06-30 | P2 | Zhejiang Doer Biologics Co., Ltd. | NCT06555640 A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 79 |
| 2025-06-30 est. | P2 | LG Chem | NCT06618196 Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age | Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Haemophilus Influenzae Type B Infection | unknown | 336 |
| 2025-06-30 est. | P1/P2 | MAXVAX Biotechnology Limited Liability Company | NCT06642558 Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above | Respiratory Syncytial Virus (RSV) | active not recruiting | 522 |
| 2025-06-30 | P2 | Guangdong Raynovent Biotech Co., Ltd | NCT06656026 Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A | Influenza a | completed | 72 |
| 2025-06-30 est. | P2 | Jemincare | NCT06664125 Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia | Hyperphosphatemia | unknown | 50 |
| 2025-06-30 est. | P3 | Vanda Pharmaceuticals VNDA | NCT06701396 Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders; Gene Mutations and | recruiting | 60 |
| 2025-06-30 est. | P2 | Akeso | NCT06756126 A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | not yet recruiting | 24 |
| 2025-06-30 | P2 | Spinogenix | NCT06903286 Extension Study of Participants From SPG302-ALS-001 | Amyotrophic Lateral Sclerosis (ALS) | terminated | 16 |
| 2025-06-30 est. | P2 | Livzon Pharmaceutical Group Inc. | NCT06963320 Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty | Circulatory Disease | recruiting | 320 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.